DreaMed Diabetes

By MobiHealthNews 04:11 pm July 5, 2018
Interest in digital health is now sprouting up all over DC, from the president’s announcement of a new AI task force to FDA Commissioner’s shout out to digital health in his budget request.   In fact, the FDA is turning to developers in the digital health space to help solve some of the country’s most difficult problems. In May, the agency announced an innovation challenge aimed at tackling the...
DreaMed Diabetes tool gets FDA approval
By Dave Muoio 08:52 am June 18, 2018
The FDA has granted Isreal-based DreaMed Diabetes a de novo request for its artificial intelligence-powered software for providers managing patients with Type 1 diabetes. “This is an innovation that can improve people’s lives and the FDA decision confirms what we believe is an important step in making a more meaningful connection between the healthcare provider and their type 1 diabetes patients...
By Dave Muoio 04:05 pm February 15, 2018
Insulin dose tool gains CE Mark. DreaMed Diabetes has received a CE Mark for its Type 1-focused clinical decision support (CDS) platform, Advisor Pro. The tool’s algorithms process data from a number of connected diabetes management devices to provide a personalized insulin dosing treatment plan. The software achieved similar glycemic control when compared to medical experts during pilot studies...
By Heather Mack 04:36 pm July 29, 2016
During the month of July, MobiHealthNews reported on 16 digital health companies that raised venture funding. The deals total $149.3 million, which is lower on average when compared to other months this year so far but that's expected for the slower news cycle in the summer. In the first half of 2016, MobiHealthNews tracked funding for digital health companies that totaled $1.27 billion, as we...
By Heather Mack 02:55 pm July 25, 2016
Israel-based DreaMed Diabetes announced this week that it has raised $3.3 million from Norma Investments, Russian businessman Roman Abramovich and one other unnamed angel. The funds will mainly be used for further development of DreaMed’s Advisor, the company's decision support software that can be licensed and embedded into partners' diabetes management platforms. For example, in February, the...